Merck & Co ties up with Xenon for CV deal
This article was originally published in Scrip
Executive Summary
Merck & Co and Xenon have agreed a drug discovery and development deal for prospective cardiovascular targets. The collaboration will focus on small molecules and is potentially worth upwards of $90 million.